GEN 1

Drug Profile

GEN 1

Alternative Names: EGEN-001; IL-12 gene therapy - Celsion Corporation; IL-12 gene therapy - EGEN; IL-12 gene therapy - Expression Genetics; Interleukin-12 gene therapy - Celsion Corporation; Interleukin-12 gene therapy - EGEN; Interleukin-12 gene therapy - Expression Genetics; phIL-12-005/PPC

Latest Information Update: 18 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Expression Genetics
  • Developer Celsion Corporation; Gynecologic Oncology Group
  • Class Cytokine genes; Gene therapies; Immunotherapies; Interleukins
  • Mechanism of Action Gene transference; Immunomodulators; Interleukin 12 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Preclinical Glioblastoma
  • No development reported Colorectal cancer

Most Recent Events

  • 30 Jun 2018 Phase-I/II clinical trials in Fallopian tube cancer (Late-stage disease, Newly diagnosed, Neoadjuvant therapy, Metastatic disease) in USA (Intraperitoneal) (NCT03393884)
  • 30 Jun 2018 Phase-I/II clinical trials in Ovarian cancer (Late-stage disease, Newly diagnosed, Metastatic disease, Neoadjuvant therapy) in USA (Intraperitoneal) (NCT03393884)
  • 30 Jun 2018 Phase-I/II clinical trials in Peritoneal cancer (Late-stage disease, Newly diagnosed, Metastatic disease, Neoadjuvant therapy) in USA (Intraperitoneal) (NCT03393884)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top